Guidelines

• NCCN Guidelines Version 3.2023

Evidence Blocks

• NCCN Guidelines with Evidence Blocks Version 3.2023

Frameworks

• Basic Resources (English) Version 3.2022

• Core Resources (English) Version 3.2022

• Enhanced Resources (English) Version 3.2022

Guidelines for Patients

• Non-Small Cell Lung Cancer - Early and Locally Advanced-English Version 2023

• Non-Small Cell Lung Cancer - Metastatic-English Version 2023

• Non-Small Cell Lung Cancer - Metastatic-Korean Version 2021

• Non-Small Cell Lung Cancer - Early and Locally Advanced-Ukrainian Version 2021

• Non-Small Cell Lung Cancer - Metastatic-Ukrainian Version 2021

Educational Events and Programs

Calendar of Events

Continuing Education

• NCCN Guidelines® Insights - Non–Small Cell Lung Cancer, Version 2.2023

• Recorded Presentation from the NCCN Pharmacy Updates: Updates in Biomarker-Driven Therapy in Non-Small Cell Lung Cancer

• Updates in Biomarker Testing in Non-Small Cell Lung Cancer

• Archived Monthly Oncology Tumor Boards: Neoadjuvant and Adjuvant Therapy for Patients with Resectable Early-Stage and Locally Advanced Non-Small Cell Lung Cancer

• Screening for Lung Cancer: An Expert Review

• Targeted Therapy for Metastatic Non-Small Cell Lung Cancer

• Challenging Case Review: Non-Small Cell Lung Cancer

• Clinical Scenario #4: Applying Biomarkers in Non-Small Cell Lung Cancer

• Unlocking the Potential of Neoadjuvant and Adjuvant Immunotherapy in Resectable NSCLC: The Role of Checkpoint Inhibitors

International

Disclosures

• Disclosure Policy

• Panel Member Disclosures

• Panel Member Disclosures by Meeting Date

• End User License Agreement